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ABSTRACT 
Skeletal muscle plasticity is regulated by a wide range of factors, among which 
environmental stimuli such as exercise and nutrition play a central role. Importantly, 
changes in skeletal muscle phenotype exert a direct impact on health and risk to premature 
death. In fact, physical inactivity promotes the development of diseases like cancer, heart 
diseases, skeletal muscle wasting and type 2 diabetes. In contrast, exercise training has been 
extensively shown to lower the risk of these pathologies, mainly by enhancing the metabolic 
fitness, mass and function of skeletal muscle tissue. Skeletal muscle remodelling is highly 
regulated at the transcriptional level through the coordinated interplay between 
transcription factors and coregulators. The transcription factors estrogen-related receptor α 
(ERRα) and proliferator-activated receptor β/δ (PPARβ/δ) play a key regulatory function of 
skeletal muscle metabolism, while their coactivator PPARγ coactivator 1α (PGC-1α) and 
corepressor nuclear receptor corepressor 1 (NCoR1) have emerged as potential modulators 
of skeletal muscle plasticity. However, the physiological role and the mechanisms by which 
PGC-1α and NCoR1 regulates skeletal muscle phenotype and function are not fully 
understood. 
In order to define the role of NCoR1 in skeletal muscle plasticity and to identify its 
potential interplay with PGC-1α, we initially characterized NCoR1 muscle-specific knockout 
(mKO) mice. We observed that the deletion of NCoR1 in skeletal muscle resulted in 
enhanced oxygen consumption (VO2) during treadmill running, lower maximal force and 
increased ex vivo fatigue resistance under maximal stimulation. Interestingly, microarray 
analysis of NCoR1 mKO and PGC-1α muscle-specific transgenic (mTg) mice skeletal muscle 
revealed an up-regulation of genes related to oxidative metabolism in both mouse models. 
Consistently, we found that PGC-1α knockdown in cultured myotubes inhibited the up-
regulation of mitochondrial enzymes induced by NCoR1 knockdown. Moreover, ERRα and 
PPARβ/δ were identified as direct targets of both NCoR1 and PGC-1α. However, only the 
inhibition of ERRα was able to block the effects of NCoR1 knockdown in C2C12 myotubes. 
Subsequently, during the second study of this thesis, the functional interplay between PGC-
1α and PPARβ/δ was further determined by using different genetic mouse models. 
Surprisingly, our data demonstrated that the PGC-1α-PPARβ/δ axis does not control whole 
body metabolism under basal conditions. Actually, PPARβ/δ was found to be dispensable for 
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the positive effects of PGC-1α on whole body (e.g. VO2) and skeletal muscle oxidative 
metabolism. Altogether, these studies demonstrate that, under basal conditions, NCoR1 and 
PGC-1α modulate skeletal muscle oxidative metabolism specifically by controlling ERRα-
mediated gene expression. 
Finally, skeletal muscle remodelling induced by chronic overload was studied by using 
the experimental model of synergist ablation (SA). Interestingly, SA has been shown to 
induce skeletal muscle hypertrophy through the activation of the mammalian target of 
rapamycin complex 1 (mTORC1), while mTORC1 can enhance skeletal muscle oxidative 
metabolism by regulating the PGC-1α-Ying Yang 1 transcriptional complex. Accordingly, in 
the last study of this thesis the potential function of the mTORC-1-PGC-1α axis in SA-induced 
skeletal muscle remodelling was defined by using PGC-1α mTg and mKO mice. As expected, 
SA strongly induced mTORC1 activation and skeletal muscle hypertrophy, though these 
effects were independent of PGC-1α. Moreover, SA down-regulated PGC-1α mRNA levels, 
consistent thus with the global repression of glycolytic and oxidative metabolism. Functional 
analyses further demonstrated that, SA promoted a switch toward a slow-contractile 
phenotype characterized by lower peak force and higher fatigue resistance, which was not 
altered in PGC-1α mTg mice. However, genetic ablation of PGC-1α preserved peak force 
after SA, an effect that seems to be related to the regulation of myosin heavy chain 2B, 
myosin regulatory light chain (MLC) and MLC kinase 2 by PGC-1α. Hence, we have found that 
PGC-1α is not involved in skeletal muscle hypertrophy and metabolic remodelling induced by 
SA, while this coactivator seem to be partially involved in the functional adaptations to SA. 
However, SA did not fully resemble the effects of resistance exercise in human skeletal 
muscle, thus the relevance of PGC-1α as a therapeutic target aiming at promoting skeletal 
muscle growth remains to be further explored under different conditions. 
Therefore, the studies performed during this thesis have revealed new molecular 
mechanisms by which coregulators mediate skeletal muscle plasticity, especially related with 
the control of oxidative metabolism. Considering the relevance of skeletal muscle metabolic 
fitness in the development and prevention of metabolic diseases, these data has direct 
biomedical relevance. However, the therapeutic potential of the mechanisms here described 
remain to be defined in future studies. 
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ABBREVIATIONS 
1RM 1 repetition maximum 
AMPK AMP-activated protein kinase 
ATF2 activating transcription factor 2 
CBP CREB binding protein 
CREB cAMP-response element binding protein 
CSA fibre cross sectional-area 
DAD deacetylase activation domain 
EDL extensor digitorum longus 
ERR estrogen-related receptor 
ETC electron transport chain 
FOXO3 fork-head transcription factor O3 
GCN5 general control of amino-acid synthesis 5 
GO gene ontology 
GPS2 G protein pathway suppressor 2 
HAT histone acetyltransferase 
HDAC histone deacetylase 
HID histone interaction domain 
IGF-1 insulin-like growth factor 1 
MAFbx muscle atrophy F-box 
MAPK mitogen-activated protein kinase 
MEF2 myocyte enhancer factor 2 
MLC myosin regulatory light chain 
MLCK2 MLC kinase 2 
mTORC1 mammalian target of rapamycin complex 1 
MuRF1 muscle RING-finger protein-1 
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NCoR1 nuclear receptor corepressor 1 
NCoR2 nuclear receptor corepressor 2 
NFκB nuclear factor-kappaB 
NRF nuclear respiratory factor 
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PKD protein kinase D 
PPAR peroxisome proliferator-activated receptor 
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RID receptor interaction domains 
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TFAM mitochondrial transcription factor A 
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YY1 Yin Yang 1 
 
4 
 
CHAPTER 1: Introduction 
Skeletal muscle remodelling in health and disease 
Skeletal muscle is one of the most abundant tissues in mammals, with a 
central function in the modulation of whole body homeostasis and health status. 
This tissue plays an important metabolic function since it represents the main place 
of energy expenditure, glycogen storage and insulin-stimulated glucose uptake (Egan 
and Zierath, 2013). Skeletal muscle is formed by a heterogeneous population of 
fibres, exhibiting different metabolic and functional properties. Accordingly, skeletal 
muscle fibres are classified as slow-oxidative (type 1) and fast-glycolytic (type 2) 
fibres, with type 2 fibres further distinguished as 2A, 2B and 2X. Type 1 fibres show 
the highest mitochondrial content, oxidative capacity and fatigue resistance, while 
they predominantly express myosin heavy chain 1 (MyHC-1) and slow-twitch 
properties (Schiaffino and Reggiani, 2011). On the other hand, type 2B and 2X fibres 
exhibit high glycolytic metabolism, low mitochondrial content, low fatigue resistance 
and fast-twitch properties, while type 2A fibres have intermediate characteristics 
between type 1 and 2B/X fibres (Schiaffino and Reggiani, 2011). Moreover, type 2A, 
2B and 2X fibres specifically express MyHC-2A, MyHC-2B and MyHC-2X, respectively, 
though MyHC-2B is not detected in human skeletal muscle (Schiaffino and Reggiani, 
2011). These divergent phenotypes are regulated by a highly specific subset of genes 
that differentially lead to expression of proteins involved in both skeletal muscle 
metabolism and contractility (Drexler et al., 2012; Wu et al., 2003). For instance, 
proteomic analysis of the slow-oxidative muscle soleus shows an overrepresentation 
of gene ontology (GO) terms related to mitochondria and oxidative metabolism, 
whereas overrepresented GO terms in the fast-glycolytic muscle extensor digitorum 
longus (EDL) are related to sarcoplasmic reticulum and carbohydrate metabolism 
(Drexler et al., 2012). Skeletal muscle phenotype is therefore regulated at the 
transcriptional level, with different transcription factors and coregulators modulating 
the expression or repression of fibre type-specific genes (Baar, 2010; Coffey and 
Hawley, 2007; Egan and Zierath, 2013; Gundersen, 2011). 
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Skeletal muscle remodelling by physical inactivity 
Different stimuli have been shown to modify skeletal muscle phenotype, with 
environmental factors like nutrients and physical activity playing a major role in the 
regulation of this process. A sedentary life style has been recognized as the main 
pathogenic factor of non-communicable diseases (e.g. obesity and type 2 diabetes), 
which ultimately lead to premature death worldwide (Booth et al., 2008; Lee et al., 
2012; Thyfault and Booth, 2011). Physical inactivity has been reported to increase 
the risk of different types of cancer, heart diseases and type 2 diabetes among other 
diseases (Booth and Laye, 2009). The increase in morbidity and mortality induced by 
a sedentary life style is the consequence of the maladaptation of a wide spectrum of 
tissues and organs, which ultimately lead to impaired whole body homeostasis 
(Figure 1). Importantly, among the different tissues involved in the development of 
metabolic diseases, skeletal muscle seems to play a mayor pathogenic role. Insulin 
resistance in skeletal muscle has been shown to drive the development of whole 
body metabolic syndrome (Kim et al., 2000; Petersen et al., 2007), a process that has 
been directly linked to lower levels of physical activity (Alibegovic et al., 2009; 
Mikines et al., 1991; Richter et al., 1989). In fact, skeletal muscle metabolic function 
is severely impaired by physical inactivity, which is characterized by a lower mRNA, 
protein and activity levels of different key regulatory proteins of both glycolytic and 
oxidative metabolism (Alibegovic et al., 2010; Bienso et al., 2012; Brocca et al., 2012; 
Chen et al., 2007; Ringholm et al., 2011). Importantly, impaired skeletal muscle 
energy metabolism has been extensively shown to be a hallmark of a number of 
non-communicable diseases. The metabolic impairment induced by physical 
inactivity has been linked to the repression of a specific subset of genes involved in 
aerobic metabolism and substrate turnover. Skeletal muscle from type 2 diabetic 
patients exhibit a gene expression signature characterized by the down-regulation of 
genes involved in oxidative metabolism (Barres et al., 2013; Barres et al., 2009; 
Mootha et al., 2003; Patti et al., 2003), implying that transcription factors and 
coregulators are deregulated in the context of metabolic diseases. 
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Figure 1 Pathological effects of physical inactivity at the whole body level (from 
(Booth and Laye, 2009)). 
 
Furthermore, physical inactivity as well as several pathologies have been 
shown to promote a decrease in skeletal muscle mass, fibre cross sectional-area 
(CSA) and force generation (Figure 1). Importantly, skeletal muscle mass loss 
contributes to the progression and mortality associated with diseases such as 
cancer, heart failure, chronic obstructive pulmonary disease and renal failure (Glass 
and Roubenoff, 2010). It should be noted that skeletal muscle atrophy can also take 
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place in response to non-pathological conditions, including aging and caloric 
restriction (Glass and Roubenoff, 2010; Parr et al., 2013), indicating thus that 
environmental stimuli also play an important role in the modulation of skeletal 
muscle mass. Indeed, although a wide spectrum of pharmacological approaches 
have been undertaken to combat skeletal muscle wasting, resistance exercise 
remains the most efficient strategy to maintain or enhance muscle mass (Glass and 
Roubenoff, 2010; von Haehling et al., 2012). Skeletal muscle atrophy induced by 
physical inactivity is directly associated to a decrease in the rate of skeletal muscle 
protein synthesis, while the rate of protein degradation exhibit an opposite response 
(Bodine, 2013). These changes in protein turnover following skeletal muscle 
unloading have been suggested to be highly regulated at the transcriptions levels. 
Actually, the gene expressions signature linked to skeletal muscle atrophy shows a 
clear association to biological process regulating protein degradation, mainly linked 
to the ubiquitin proteasome pathway (Bodine, 2013; Schiaffino et al., 2013). 
Therefore, the skeletal muscle phenotype undergoes extensive remodelling 
following physical inactivity and during pathological conditions, which is mainly 
reflected by a global repression of different metabolic-related genes, lower oxidative 
capacity, skeletal muscle atrophy and lower maximal force. Collectively, these 
changes in skeletal muscle phenotype are thought to affect whole body function and 
to increase the prevalence and development of non-communicable diseases. 
 
Skeletal muscle remodelling by physical activity 
In stark contrast to physical inactivity, a higher exercise performance and 
metabolic fitness are strongly associated to a decreased prevalence of metabolic 
diseases and premature death (Booth and Roberts, 2008). Exercise training can 
accordingly lower the risk of a number of diseases, including type 2 diabetes, 
hypertension, cancer and skeletal muscle wasting (Booth and Roberts, 2008). 
Consequently, irrespectively of the type of exercise, physical activity is currently 
considered as one of the most efficient therapeutic approaches to treat metabolic 
diseases (Egan and Zierath, 2013), whereas resistance exercise is thought to be more 
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effective for the treatment of muscle wasting-related diseases (Bodine, 2013; Glass 
and Roubenoff, 2010). However, whole body and skeletal muscle adaptations to 
exercise are very specific, with endurance and resistance exercise representing two 
extremes in the spectrum of exercise modes and functional adaptations. 
Endurance or aerobic exercise is characterized by exercise performed against 
a low load for a long period of time, in which most of the energetic demands are 
provided by the aerobic oxidation of both carbohydrate and fatty acids. Endurance 
training induces a wide range of beneficial adaptations, such as an improved body 
composition, higher insulin sensitivity, lower blood pressure and improved 
cardiovascular function (Table 1). This kind of exercise also increases maximal 
oxygen consumption (VO2max), which is associated to an increased fatty acid 
oxidation and skeletal muscle glycogen sparing at submaximal exercise. Collectively, 
these adaptations contribute to the improved endurance performance and 
metabolic health observed after endurance training, though skeletal muscle-specific 
play a key role in the regulation of these adaptations (Holloszy and Coyle, 1984). In 
fact, besides increasing skeletal muscle vascularization, endurance training boosts 
mitochondrial content and metabolic function of skeletal muscle fibres. The effects 
of endurance exercise on mitochondrial function was first described in rat skeletal 
muscle, where endurance training was shown to increase mitochondrial content, the 
activity of mitochondrial enzymes and mitochondrial respiration (Holloszy, 1967). 
Importantly, similar results have been reported both in rodent and human skeletal 
muscle, strongly supporting the positive effects of endurance exercise on skeletal 
muscle oxidative metabolism (Egan and Zierath, 2013; Holloszy and Coyle, 1984). 
Skeletal muscle remodelling induced by endurance exercise is regulated by a wide 
range of pathways and molecules, but gene transcription is thought to play a key 
regulatory mechanism (Coffey and Hawley, 2007; Egan and Zierath, 2013; 
Gundersen, 2011). In fact, it has been demonstrated that endurance trained athletes 
exhibit a highly specific gene expression signature in skeletal muscle tissue, in which 
GO terms related to mitochondrial structure and function are significantly 
overrepresented (Stepto et al., 2009). Furthermore, exercise training enhances 
skeletal muscle oxidative metabolism by  inducing transient changes in the mRNA 
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levels of metabolic-related genes that in the long term result in a progressive 
increase of their protein content (Coffey and Hawley, 2007; Egan and Zierath, 2013; 
Perry et al., 2010), indicating that gene transcription is an early process in the control 
of skeletal muscle remodelling. 
On the other hand, resistance or strength training is characterized by exercise 
performed against a high load (e.g. 80% of 1 repetition maximum (1RM)), which is 
normally above the aerobic capacity of the active muscles. At the whole body level, 
unlike endurance exercise, resistance exercise induces a mild impact on the 
cardiovascular system and oxidative capacity, whereas it significantly increases lean 
mass, bone mineral density and basal metabolic rate (Table 1). Moreover, resistance 
exercise also produce specific adaptations in skeletal muscle tissue, among which 
the increase in fibre size, myofibrillar protein synthesis and force generation are the 
most characteristic changes (Table 1). Improvements in force generation however 
are initially due to neural adaptations and thus in the absence of skeletal muscle 
hypertrophy, with skeletal muscle-specific adaptations playing a major role following 
chronic resistance exercise (Fry, 2004). Interestingly, most of the adaptations 
observed in skeletal muscle following resistance training are thought to be directly 
related to the intensity at which exercise is performed, with resistance exercise 
performed at 80-90% of 1RM resulting in maximal increases in both fibre CSA and 
maximal force (Fry, 2004). Resistance training has been proposed to induce a fibre 
type switch toward type 2A fibres, which is consistent with the high recruitment of 
this fibre type during this kind of exercise (Egan and Zierath, 2013; Fry, 2004). 
Furthermore, mechanical overload of mouse skeletal muscle significantly increases 
protein synthesis, with type 2A fibres showing the highest increase in CSA (Goodman 
et al., 2012). Consistent with the higher rate of protein synthesis induced by 
resistance exercise, it has been demonstrated that mechanical overload also induces 
a significant increase in ribosomal content, an effect that is highly regulated at the 
transcriptional level (Goodman et al., 2011; von Walden et al., 2012). Importantly, 
gene transcription seems to also be a key process in the modulation of skeletal 
muscle remodelling induced by resistance exercise, since strength trained athletes 
show a very specific gene expression signature in which genes related to protein 
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synthesis are significantly up-regulated in skeletal muscle (Stepto et al., 2009). 
Therefore, even though endurance and resistance training induce divergent effects 
on skeletal muscle remodelling, it appears that adaptations to both of these types of 
exercise require the regulation of specific gene expression signatures. 
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Table 1 Whole body and skeletal muscle-specific adaptations to endurance and 
resistance exercise (from (Egan and Zierath, 2013)). 
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Transcriptional coregulators and skeletal muscle remodelling 
Gene transcription is highly regulated by the coordinated interaction 
between transcription factors and coregulators. Transcription factors are a family of 
proteins able to interact with specific binding sites along the DNA known as response 
elements or cis-regulatory elements, which are mainly located at the promoter 
region of target genes. In contrast, coregulators are not able to directly interact with 
the DNA, but instead they form multi-protein complexes that interact with 
transcription factors and thus regulate their activity. Importantly, coregulators can 
be classified as coactivators or corepressors if they promote or repress gene 
transcription, respectively. The main mechanism by which coregulators modulate 
gene transcription is by recruiting different proteins with histone acetyltransferase 
(HAT) and deacetylase (HDAC) activity. Consequently, gene transcription is mainly 
activated when transcription factors recruit coactivator complexes containing HAT 
activity that induce an open conformation of the chromatin, whereas corepressors 
promote the opposite effect through HDAC-induced chromatin condensation (Figure 
2). The role of coregulators in skeletal muscle physiology has not been fully 
elucidated, but the peroxisome proliferator-activated receptor γ (PPARγ) coactivator-
1α (PGC-1α) and the nuclear receptor corepressor 1 (NCoR1) have emerged as 
potential regulators of skeletal muscle plasticity. 
 
Figure 2 Main mechanism by which transcriptional corepressors (CoRep) and 
coactivators (CoAct) modulate gene transcription (from (Mottis et al., 2013)). TF: 
transcription factor, HAT: histone acetyltransferase, HDAC: histone deacetylase, Ac: 
acetylation. 
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The coactivator PGC-1α 
The transcriptional coactivator PGC-1α was initially described as a coactivator 
of the nuclear receptor PPARγ in brown adipose tissue (Puigserver et al., 1998), while 
subsequent studies identified PGC-1β (Kressler et al., 2002; Lin et al., 2002a) and 
PGC-1-related coactivator (PRC) (Andersson and Scarpulla, 2001) as additional 
members of the PGC-1 family of coactivators. The PGC-1α protein can interact with 
its target transcription factors through three LXXLL motifs located in the N-terminal 
transcriptional activation domain (Figure 3). In addition, the PGC-1α protein contains 
a central regulatory domain involved in transcriptional repression, while the C-
terminus domain contain a serine/arginine rich domain (RS) and an RNA binding 
domain that have been involved in protein-protein interaction and the regulation of 
mRNA splicing, respectively (Figure 3). However, despite the similarities between the 
member of the PGC-1 family of coactivators, PGC-1β and PRC do not recapitulate all 
of the effects induced by PGC-1α (Lin et al., 2005; Scarpulla et al., 2012). PGC-1α 
lacks enzymatic activity and its positive effects on gene transcription have been 
shown to be significantly enhanced by the recruitment of HAT proteins, including 
cAMP-response element binding protein (CREB) binding protein (CBP), p300 and 
steroid receptor coactivator-1 (SRC-1) (Puigserver et al., 1999; Wallberg et al., 2003). 
Interestingly, PGC-1α has been proposed to modulate gene transcription by 
recruiting the TRAP/Mediator complex and mRNA processing through its C-terminal 
domain (Monsalve et al., 2000; Wallberg et al., 2003). Finally, also in the C-terminal 
domain, PGC-1α has been shown to interact with BRG1-associated factor 60a that 
consequently allows the recruitment of the switch/sucrose non-fermentable 
chromatin-remodelling complex (Li et al., 2008). The multi-protein complex formed 
by PGC-1α hence contain proteins able to couple chromatin remodelling and mRNA 
processing, allowing thus the efficient regulation of gene transcriptions (Figure 3). 
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Figure 3 Protein structure and main components of the PGC-1α multi-protein 
complex (from (Lin et al., 2005)). 
 
PGC-1α and skeletal muscle remodelling 
The PGC-1α coactivator complex interacts with and regulates the activity of a 
number of transcription factors involved in a wide range of biological functions, 
among which energy metabolism, protein degradation and angiogenesis are 
particularly relevant for skeletal muscle function (Figure 4). Actually, PGC-1α has 
been shown to positively regulate the expression of different nuclear and 
mitochondrial encoded genes involved in metabolic pathways such as the TCA cycle, 
fatty acid β-oxidation and the electron transport chain (ETC) (Scarpulla et al., 2012). 
Moreover, PGC-1α overexpression specifically in skeletal muscle promotes a fibre 
type switch toward a slow-oxidative phenotype through the regulation of myocyte 
enhancer factor 2 (MEF2) (Lin et al., 2002b; Summermatter et al., 2012). 
Importantly, these transcriptional changes directly improve VO2peak, endurance 
performance and ex vivo fatigue resistance (Calvo et al., 2008; Lin et al., 2002b; 
Summermatter et al., 2012), demonstrating the physiological relevance of this 
coactivator. The mechanism by which PGC-1α enhances oxidative metabolism 
involves the activation of a specific subset of transcription factors, among which the 
nuclear respiratory factor 1 (NRF1), NRF2, estrogen-related receptor α (ERRα), 
PPARα and PPARβ/δ have been proposed to play key regulatory functions 
(Ehrenborg and Krook, 2009; Lin et al., 2005). Importantly, PGC-1α indirectly 
modulates the expression of mitochondrial encoded genes by inducing the 
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expression of mitochondrial transcription factor A (TFAM) via NRF1 and NRF2 (Lin et 
al., 2005). PGC-1α has also been shown to increase the transcriptional activity of Yin 
Yang 1 (YY1) in a mammalian target of rapamycin complex 1 (mTORC1) dependent 
manner, thus boosting skeletal muscle oxidative metabolism (Blattler et al., 2012; 
Cunningham et al., 2007). Interestingly, in addition to enhance substrate utilisation 
via aerobic metabolism, PGC-1α also promotes lipid storage in skeletal muscle fibres 
by activating the liver X receptor α (Summermatter et al., 2010), resembling the 
metabolic adaptations induced by exercise in human skeletal muscle (van Loon and 
Goodpaster, 2006). Furthermore, the activation of ERRα by PGC-1α induces the 
expression of the vascular endothelial growth factor and, consequently, promotes 
angiogenesis in skeletal muscle (Arany et al., 2008; Chinsomboon et al., 2009). These 
data indicate that PGC-1α overexpression in skeletal muscle is sufficient to control 
most of the metabolic and functional adaptation induced by endurance exercise. 
Interestingly, even though PGC-1α acts primarily as a transcriptional 
coactivator, it has also been shown that PGC-1α can repress the expression of genes 
involved in skeletal muscle atrophy. However, the mechanism by which PGC-1α 
repress gene expression is currently unknown. Reporter gene assay experiments 
have demonstrated that PGC-1α can significantly decrease the transcriptional 
activity of the transcription factors fork-head transcription factor O3 (FOXO3) and 
nuclear factor-kappaB (NFκB) (Brault et al., 2010; Sandri et al., 2006). The repression 
of these transcription factors by PGC-1α is highly relevant, since it prevents skeletal 
muscle mass loss during both aging and following denervation (Brault et al., 2010; 
Sandri et al., 2006; Wenz et al., 2009). Actually, FOXO3 induce the expression of the 
muscle-specific E3 ubiquitin ligases muscle RING-finger protein-1 (MuRF1; also 
known as Trim63) and muscle atrophy F-box (MAFbx; also known as atrogene 1 and 
Fbxo32), which are key regulators of skeletal muscle unloading-induced atrophy 
(Bodine et al., 2001). Both of these E3 ubiquitin ligases are up-regulated in response 
to skeletal muscle unloading and their genetic ablation decreases skeletal muscle 
mass loss following unloading (Bodine et al., 2001). Consistent with the effects of 
PGC-1α on muscle mass and FOXO3 activity, the overexpression of this coactivator 
attenuates MuRF1 and MAFbx up-regulation observed during skeletal muscle 
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atrophy (Sandri et al., 2006), effect that has been linked to lower levels of protein 
degradation (Brault et al., 2010). Moreover, it has been recently shown that a new 
identified transcript variant of PGC-1α called PGC-1α4 is able to promote skeletal 
muscle hypertrophy and protect against atrophy when overexpressed in skeletal 
muscle (Ruas et al., 2012). PGC-1α thus seems to be a versatile coregulator, 
regulating energy metabolism and protein degradation through both transcriptional 
activation and repression. 
 
 
Figure 4 Main transcription factors and biological process regulated by PGC-1α in 
skeletal muscle (from (Pérez-Schindler and Handschin, 2013)). ERRα: estrogen-
related receptor α, NRF1/2: nuclear respiratory factor 1 and 2, FoxO1/3: forkhead 
box O1/3, TFAM: mitochondrial transcription factor A, MEF2: myocyte enhancer 
factor 2, PPAR: peroxisome proliferator-activated receptor, RORα/γ: retinoic acid 
receptor-related orphan receptor α/γ, LXRα: liver X receptor α, NFκB: Nuclear 
factor-kappaB, RE: transcription factor response elements, A: histone acetylation. 
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Regulation of PGC-1α expression and activity in skeletal muscle 
Among the different stimuli promoting skeletal muscle PGC-1α expression 
and activity, exercise exerts the strongest effects (Egan and Zierath, 2013; Pérez-
Schindler and Handschin, 2013). In fact, skeletal muscle PGC-1α expression levels are 
higher in trained subjects, while it is significantly down-regulated by physical 
inactivity (Alibegovic et al., 2010; Brocca et al., 2012; Kramer et al., 2006). The 
effects of skeletal muscle contraction on PGC-1α expression were first described in 
rodent skeletal muscle, where both acute and chronic exercise was shown to 
significantly up-regulate the mRNA and protein levels of this coactivator in skeletal 
muscle (Baar et al., 2002; Goto et al., 2000; Terada et al., 2002; Terada et al., 2005; 
Terada and Tabata, 2004). Importantly, a single session of either endurance or high-
intensity interval training have been shown to strongly induce a transient increase of 
PGC-1α mRNA in human skeletal muscle (Bartlett et al., 2012; Coffey et al., 2006; 
Gibala et al., 2009; Pilegaard et al., 2003; Russell et al., 2005), which when repeated 
over time increases PGC-1α protein levels (Burgomaster et al., 2008; Hood et al., 
2011; Little et al., 2011; Little et al., 2010; Mathai et al., 2008; Perry et al., 2010; 
Russell et al., 2003). Interestingly, changes in PGC-1α expression induced by exercise 
are thought to be sensitive to the intensity at which exercise is performed, with 
higher intensities resulting in bigger effects (Egan et al., 2010; Nordsborg et al., 2010; 
Tadaishi et al., 2011). 
Exercise-induced PGC-1α expression involves a wide number of signal 
pathways, though only few proteins seem to be essential (Figure 5). In fact, skeletal 
muscle contraction mediates the transcription of this coactivator by inducing the 
recruitment of the transcription factors MEF2 and activating transcription factor 2 
(ATF2) at the promoter region of the PGC-1α gene (Akimoto et al., 2004). The up-
regulation of PGC-1α mRNA induced by MEF2 and ATF2 following skeletal muscle 
contraction has been reported to require the activation of protein kinase D (PKD) 
and p38 mitogen-activated protein kinase (MAPK) (Akimoto et al., 2008; Pogozelski 
et al., 2009). In addition to the activation and recruitment of these essential 
transcription factors to the PGC-1α promoter, exercise has been also shown to 
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reduces DNA methylation levels, decreasing thus the transcriptional repression of 
this gene (Barres et al., 2012). Importantly, PGC-1α activity is also regulated at the 
post-translational level by different modification, such as phosphorylation, 
acetylation and methylation among others (Fernandez-Marcos and Auwerx, 2011). 
Exercise however seems to mainly modulate PGC-1α activity through 
phosphorylation and acetylation. On one hand, skeletal muscle contraction can 
efficiently increase the activity of AMP-activated protein kinase (AMPK) and p38 
MAPK (Egan and Zierath, 2013), both of which have been shown to directly 
phosphorylate and activate PGC-1α (Jager et al., 2007; Puigserver et al., 2001). These 
data suggest that skeletal muscle contraction-mediated PGC-1α activation might be 
dependent of its phosphorylation by AMPK and p38 MAPK. On the other hand, PGC-
1α can be acetylated and deacetylase by sirtuin 1 (SIRT1) and general control of 
amino-acid synthesis 5 (GCN5), respectively (Lerin et al., 2006; Rodgers et al., 2005). 
Exercise has been also suggested to activate PGC-1α by promoting its deacetylation, 
a process that is thought to be regulated by the interplay between AMPK and SIRT1 
(Canto et al., 2010). In addition, it has been recently reported that exercise decrease 
PGC-1α acetylation levels mainly by decreasing its interaction with the acetyl 
transferase GCN5 rather than through SIRT1-mediated deacetylation (Philp et al., 
2011). The effects of exercise on PGC-1α activity seem to involve a complex interplay 
between phosphorylation and acetylation, but the precise mechanism and proteins 
regulating these processes need to be further studied. 
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Figure 5 Schematic representation of the signal pathways regulating PGC-1α 
expression and activity in skeletal muscle (from (Pérez-Schindler and Handschin, 
2013)). 
 
The corepressor NCoR1 
Similar to PGC-1α, the transcriptional corepressor NCoR1 does not exhibit 
enzymatic activity and it regulates gene transcription by forming a large multi-
protein complex. While NCoR1 and its homolog protein NCoR2 (also known as 
silencing mediator of retinoic acid and thyroid hormone receptor, SMRT) were first 
found to mediate ligand-independent repression of the thyroid hormone and the 
retinoic acid receptor (Chen and Evans, 1995; Horlein et al., 1995), these corepressor 
have been shown to interact with and repress a wide range of transcription factors 
(McKenna and O'Malley, 2010; Mottis et al., 2013). The protein structure of these 
corepressors is highly similar (Figure 6), mainly characterized by the presence of 
three repression domains (RD) that allow the recruitment of proteins able to inhibit 
gene transcription. Interestingly, NCoR1 is able directly interact with histones 
through their histone interaction domain (HID), while it can also interact and 
enhance HDAC3 activity through their deacetylase activation domain (DAD) (Ishizuka 
and Lazar, 2005). Moreover, the NCoR1 protein also contains three receptor 
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interaction domains (RID) located in the C-terminal domain that allow the direct 
interaction with different target transcription factors (Webb et al., 2000). The NCoR1 
complex can be formed by different proteins in a context dependent manner (Mottis 
et al., 2013), but G protein pathway suppressor 2 (GPS2), transducin β-like 1 (TBL1), 
TBL-related 1 (TBLR1) and HDAC3 represent the core subunits (Yoon et al., 2003). 
Collectively, the NCoR1 protein contains key functional domains that allow the 
interaction with specific transcription factors and the regulation of chromatin 
condensation, which consequently leads to transcriptional repression. 
 
 
Figure 6 Protein structure of NCoR1 and NCoR2 (also known as SMRT; from (Mottis 
et al., 2013)). 
 
NCoR1 and skeletal muscle remodelling 
 In stark contrast to PGC-1α, the role of NCoR1 in the control of skeletal 
muscle phenotype and function remains poorly understood. This corepressor 
however has been implicated in the control of skeletal muscle cell differentiation by 
modulating the expression of key regulatory proteins of this process such as MyoD, 
TRα1 and Csl (Bailey et al., 1999; Busson et al., 2005; Kitamura et al., 2007). 
Importantly, NCoR1 has been demonstrated to directly regulate proteins that play a 
relevant function in skeletal muscle plasticity, including HDAC3, PPARs and the 
regulatory subunit of phosphatidylinositol 3-kinase (PI3K) p85α among others 
(Furuya et al., 2007; Ishizuka and Lazar, 2005; McKenna and O'Malley, 2010). The 
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study of NCoR1 in vivo has been mainly limited by the embryonic lethality exhibited 
by NCoR1 global knockout mice (Jepsen et al., 2000), but conditional knockout 
mouse model have recently been generated and revealed the involvement of NCoR1 
in the control of energy metabolism (Li et al., 2011; Yamamoto et al., 2011). Further 
supporting the metabolic function of NCoR1, it has been shown that disruption of 
NCoR1-HDAC3 interaction enhances whole body oxidative metabolism, improves 
insulin sensitivity and alters circadian behaviour (Alenghat et al., 2008). The effects 
of NCoR1 on the circadian clock depend on the regulation of the transcription factor 
Rev-erbα (Feng et al., 2011), which has recently been proposed to be a pivotal 
modulator of skeletal muscle oxidative metabolism (Woldt et al., 2013). Further 
suggesting a role of NCoR1 in skeletal muscle plasticity, the NCoR1-HDAC3 complex 
has been reported to be an essential regulator of class IIa HDACs (Fischle et al., 
2002), which are negative regulators of slow oxidative muscle fibre formation 
(Potthoff et al., 2007). These data indicate that NCoR1 is in fact able to modulate 
skeletal muscle metabolism and regulate the activity of a wide spectrum of proteins 
with known function in skeletal muscle remodelling, but future studies are required 
to fully elucidate its physiological relevance and molecular mechanism of action. 
 
Regulation of NCoR1 expression and activity in skeletal muscle 
Under basal conditions, NCoR1 seems to be equally expressed in oxidative 
and glycolytic muscles (Schuler et al., 1999; Schuler and Pette, 1998). Interestingly, 
NCoR1 expression has been proposed to be sensitive to skeletal muscle contraction. 
In fact, rat skeletal muscle shows lower levels of NCoR1 mRNA following chronic low-
frequency electrical stimulation (Schuler et al., 1999). Similarly, acute treadmill 
running has also been shown to decrease NCoR1 transcript levels in mouse skeletal 
muscle (Yamamoto et al., 2011). Consistent with the metabolic function of this 
corepressor, NCoR1 expression has been also proposed to be regulated by nutrients, 
which is reflected by the negative effects of low-glucose and high-fatty acids on 
NCoR1 mRNA levels (Yamamoto et al., 2011). Conversely, both high-glucose and 
insulin induce the up-regulation of NCoR1 in skeletal muscle (Yamamoto et al., 
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2011). Post-translational modifications can also control the effects of NCoR1 on gene 
transcription, mainly by modulating its cellular localization. The regulation of NCoR1 
activity by post-translational modifications in skeletal muscle is not well understood, 
but data from non-muscle cells has revealed that NCoR1 can be phosphorylated by 
Akt and MEKK1 (Baek et al., 2002; Hermanson et al., 2002). Phosphorylation of 
NCoR1 by these protein kinases promotes gene transcription by inducing its 
translocation from the nucleus to the cytosol (Baek et al., 2002; Hermanson et al., 
2002). Interestingly, mTORC1 activation of S6K2 has been suggested to promote 
NCoR1 nuclear localization and repression of PPARα in the liver (Kim et al., 2012; 
Sengupta et al., 2010). Importantly, most of the signal pathways promoting NCoR1 
phosphorylation are highly regulated by exercise (Egan and Zierath, 2013), strongly 
suggesting a role of NCoR1 in exercise-mediated skeletal muscle remodelling. 
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The current knowledge shows that transcriptional coregulators drive several aspects 
of skeletal muscle remodelling, mainly in the context of physical activity/inactivity and 
metabolic diseases. Of particular interest, activation of the coactivator PGC-1α has been 
extensively shown to improve skeletal muscle oxidative capacity, while the corepressor 
NCoR1 has emerged as a potential regulator of skeletal muscle plasticity. Importantly, 
among the wide spectrum of transcription factors that PGC-1α and NCoR1 modulate, ERRα 
and PPARβ/δ are the most prominent candidates to play a role in skeletal muscle. Here, by 
using different genetic mouse models, bioinformatics and cell culture approaches we aimed 
to identify the potential role and molecular mechanisms by which PGC-1α and NCoR1 
modulate skeletal muscle phenotype. Accordingly, this thesis has five specific aims: 
1. Define the role of NCoR1 in the regulation of skeletal muscle phenotype and function 
under basal conditions (study 1). 
2. Elucidate the potential interplay between NCoR1 and PGC-1α in the regulation of 
skeletal muscle oxidative metabolism (study 1). 
3. Determine the functional interplay between PGC-1α and PPARβ/δ in the regulation of 
skeletal muscle oxidative metabolism in vivo (study 2). 
4. Define whether PGC-1α regulates skeletal muscle hypertrophy induced by chronic 
mechanical overload (study 3). 
5. Determine the function of PGC-1α in the regulation of the metabolic and functional 
adaptations to chronic overload of skeletal muscle (study 3). 
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Abstract 
Physical activity improves oxidative capacity and exerts therapeutic beneficial 
effects, particularly in the context of metabolic diseases. The peroxisome 
proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α) and the nuclear 
receptor PPARβ/δ have both been independently discovered to play a pivotal role in 
the regulation of oxidative metabolism in skeletal muscle. Surprisingly, despite the 
obvious overlap in phenotypic changes, the interaction of these two factors in 
skeletal muscle in vivo remains unclear. In this study, we have found that the 
disruption of the PGC-1α-PPARβ/δ axis does not affect whole body metabolism 
under basal conditions. Importantly, PPARβ/δ seems dispensable for most of the 
effects of PGC-1α on VO2 and lactate metabolism during maximal exercise as well as 
the PGC-1α-mediated enhancement of an oxidative phenotype in skeletal muscle. 
Collectively, these results indicate that PPARβ/δ is not an essential partner of PGC-
1α in the control of skeletal muscle remodeling. 
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Introduction 
The regulation of energy metabolism in skeletal muscle is highly controlled by the 
peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α) [1]. 
PGC-1α drives the expression of a number of genes involved in catabolic processes 
leading to aerobic ATP synthesis [1], while concomitantly promoting anabolic 
processes, including de novo lipogenesis [2]. As a transcriptional coactivator, once 
activated, PGC-1α binds to and hence boosts the activity of different transcription 
factors to control various gene programs resembling an endurance-trained 
phenotype in skeletal muscle [1,3]. These metabolic adaptations are associated with 
an enhanced oxidative capacity, which consequently contributes to an increased 
skeletal muscle fatigue resistance ex vivo and exercise performance in vivo [4,5,6]. 
Importantly, exercise is in fact one of the most efficient stimuli to induce PGC-1α in 
skeletal muscle [3]. 
Among the transcription factors regulated by PGC-1α, the nuclear receptor PPARβ/δ 
has been proposed to be a key partner of PGC-1α in the regulation of skeletal muscle 
metabolism and function, though to a big extent based on cell culture and 
pharmacological based studies [7]. In this context, PGC-1α acts as a coactivator of 
PPARβ/δ [8,9,10], while PPARβ/δ can directly regulate PGC-1α expression [11,12], 
indicating that this nuclear receptor acts both upstream as well as downstream of 
PGC-1α. Furthermore, transgenic mouse models for PPARβ/δ exhibit a very similar 
phenotype compared to their counterparts for PGC-1α [4,5,13,14]. Nevertheless, 
even though the PGC-1α-PPARβ/δ axis appears to play a key role in the regulation of 
energy metabolism, the epistatic interaction between these two proteins is currently 
unclear. In this study, we therefore aimed at directly assessing the functional 
interplay between PGC-1α and PPARβ/δ in the regulation of skeletal muscle 
oxidative metabolism in vivo. 
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Results 
 
PGC-1α Overexpression and PPARβ/δ Deletion in Mouse Skeletal Muscle 
 
To elucidate the functional requirement for PPARβ/δ in the metabolic adaptations 
induced by PGC-1α, we crossed PPARβ/δ muscle-specific knockout (mKO) mice with 
PGC-1α muscle-specific transgenic (mTg) mice, referred as mKO/mTg animals. As 
expected, both mKO and mKO/mTg mice showed a significant reduction of PPARβ/δ 
mRNA specifically in skeletal muscle, while PGC-1α mRNA was strongly up-regulated 
by ~12 fold in skeletal muscle of mTg and mKO/mTg mice compared to control (CON) 
animals (Figure 1A and B). To validate the functional consequence of PPARβ/δ 
deletion in skeletal muscle, we next assessed the effects of the PPARβ/δ agonist 
GW0742 on the expression levels of PPARβ/δ target genes [7,15]. Acute treatment 
with GW0742 did not affect PPARβ/δ mRNA in gastrocnemius and plantaris muscles 
whereas uncoupling protein 3 (UCP3) mRNA levels were induced in CON, but not in 
mKO mice (Figure 1C and D). Moreover, as previously reported [15], angiopoietin-
like 4 (ANGPTL4) was strongly up-regulated by GW0742 in a way that was partially 
dependent on PPARβ/δ (Figure 1C and D). Importantly, PPARβ/δ deletion did not 
affect the transcript levels of PPARα and PPARγ (Figure 1E). We subsequently 
measured the expression levels of other transcription factors and coactivators that 
regulate energy metabolism, including the estrogen related receptors (ERRs), 
mitochondrial transcription factor A (TFAM), PGC-1β and PGC-1-related coactivator 
(PRC). The expression of these genes was altered in skeletal muscle of mTg and 
mKO/mTg mice, thus independent of PPARβ/δ gene ablation (Figure 1E). 
 
Effects of Skeletal Muscle Disruption of the PGC-1α-PPARβ/δ Axis on Whole Body 
Metabolism 
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Body composition assessment revealed equal body weight, fat mass and lean mass 
in mKO, mTg, mKO/mTg and CON mice (Figure 2A). Analysis of plasma triglycerides 
(TG), cholesterol (CHOL), low density lipoproteins (LDL) and high density lipoproteins 
(HDL) during fed and fasted state exhibited no differences except for a significant 
decrease in fed CHOL in the mKO/mTg mice (Figure 2B and C). Whole body 
metabolism was further assessed by indirect calorimetry during 48 h. No differences 
in oxygen consumption (VO2) or respiratory exchange ratio (RER) were observed 
between any of the genotypes (Figure 2D and E, Figure S1A and B). 
 
Pharmacological activation of PPARβ/δ attenuates the detrimental effects of obesity 
and type 2 diabetes on systemic glucose homeostasis [13,16,17]. In our animals, 
neither glucose nor insulin tolerance tests were significantly affected by PGC-1α 
overexpression and/or PPARβ/δ deletion in skeletal muscle in mice fed a regular 
chow diet (Figure 2F and G). Moreover, we did not find any significant differences in 
blood glucose levels in fed mice of the four different genotypes (Figure 2H). These 
findings were corroborated by unchanged mRNA expression of gene involved in 
glucose transport and catabolism such as the glucose transporter 4 (GLUT4), TBC1 
domain family member 1 (TBC1D1), phosphofructokinase (PFK) and hexokinase 2 
(HK2) in skeletal muscle of mKO, mTg and mKO/mTg mice (Figure 2I). In contrast, 
TBC1D4 (also known as Akt substrate of 160 kDa, AS160) was significantly up-
regulated exclusively in mTg animals (Figure 2I). Finally, we observed a small 
increase in total and phosphorylated Akt levels in mTg mice, with no substantial 
effect of PPARβ/δ deletion (Figure 2J). These data hence suggest that the PGC-1α-
PPARβ/δ axis is not essential for the modulation of whole body metabolism and 
glucose homeostasis under basal conditions in chow fed animals. 
 
Modulation of Skeletal Muscle Metabolism by the PGC-1α-PPARβ/δ Axis 
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Skeletal muscle PGC-1α and PPARβ/δ have both been proposed to be key regulators 
of exercise performance and lactate metabolism [18,19]. Consequently, we next 
assessed exercise performance in treadmill-based tests, which revealed a higher 
exercise performance in mTg mice as expected (Figure 3A and B). Interestingly, 
genetic ablation of PPARβ/δ in muscle did not reduce this difference when mTg/mKO 
mice were compared to CON animals (Figure 3A and B). Moreover, VO2 was 
significantly enhanced in mTg and mKO/mTg mice during maximal exercise (Figure 
3C), thus altered by PGC-1α independent of PPARβ/δ. In contrast however, the 
decrease in the RER in mTg animals was attenuated by concomitant knockout of 
PPARβ/δ (Figure 3D). Blood lactate concentration significantly increased following 
maximal exercise in CON animals (Figure 3E). This effect was attenuated in mKO 
mice and virtually abolished in both mTg and mKO/mTg mice (Figure 3E). Similarly, 
pre-exercise blood lactate levels were reduced only in the mouse models with 
elevated skeletal muscle PGC-1α (Figure 3E). Consistently, lactate dehydrogenase A 
(LDHA) and monocarboxylic acid transporters 4 (MCT4) mRNA levels were reduced 
only by PGC-1α overexpression in skeletal muscle, while in the same mice, LDHB and 
MCT1 were up-regulated (Figure 3F) reflecting an attenuated lactate production as 
well as higher catabolism. These data show that, in response to maximal exercise, 
skeletal muscle PGC-1α is a pivotal regulator of whole body metabolism, mainly in a 
PPARβ/δ independent manner. 
 
Next, we determined the functional relevance of PGC-1α and PPARβ/δ interaction in 
the regulation of skeletal muscle metabolism. We therefore determined the mRNA 
levels of different genes regulating skeletal muscle oxidative metabolism, several of 
which have been suggested to be both PGC-1α and PPARβ/δ targets. Interestingly, 
we observed that PPARβ/δ deletion in skeletal muscle did not change the transcript 
abundance of key genes involved in the TCA cycle, fatty acid β-oxidation and the 
mitochondrial electron transport chain (ETC) (Figure 4A and B). In contrast, most of 
these genes were strongly up-regulated by PGC-1α overexpression in a 
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PPARβ/δ independent manner (Figure 4A and B). In line with mRNA data, the 
assessment of protein content of different components of mitochondrial complexes 
revealed an up-regulation of these proteins both in mTg and mKO/mTg animals, 
whereas mKO and CON mice were indistinguishable (Figure 4C). We then assessed 
the metabolic muscle phenotype by determining the proportion of oxidative fiber 
using NADH staining, which revealed a higher oxidative activity and accordingly 
increased proportion of oxidative fibers in mTg and mKO/mTg mice independent on 
presence or absence of a functional PPARβ/δ gene (Figure 4D). Finally, the total 
protein content and phosphorylation levels of the key metabolic regulator AMP-
activated protein kinase (AMPK) were not different in mKO, mTg or mKO/mTg mice, 
suggesting no altered energy status in any of these models  (Figure 4E). 
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Discussion 
The oxidative phenotype of skeletal muscle is strongly linked to physical activity 
levels and it has been associated with health beneficial effects in metabolic diseases 
and other pathologies. Even though the molecular mechanisms that control exercise-
induced adaptation in skeletal muscle have not been fully elucidated, the 
transcriptional coactivator PGC-1α is thought to promote mitochondrial function, 
myofibrillar gene expression, vascularization and other gene programs that are 
characteristic of oxidative muscle fibers [1]. Interestingly, the nuclear receptor 
PPARβ/δ is able to recapitulate several of these effects [7]. However, despite the 
phenotypic overlap, the functional interaction between PGC-1α and PPARβ/δ has 
not been elucidated in this tissue so far. We now provide strong evidence indicating 
almost complete PPARβ/δ independence of PGC-1α overexpression on the metabolic 
phenotype of skeletal muscle. 
 
Importantly, supporting our hypothesis, contrary to the robust effects observed in 
PGC-1α muscle-specific transgenic mice, the enhancement of skeletal muscle 
oxidative metabolism is significantly weaker in a bona fide muscle-specific PPARβ/δ 
gain-of-function mouse model [14]. Moreover, ligand-based activation of PPARβ/δ 
only increases exercise performance in trained mice, but not in sedentary animals 
[10]. Interestingly, oxidative metabolism and exercise performance can be boosted 
by fusing the PPARβ/δ protein to the heterologous VP16 activation domain that 
strongly increases its transcriptional activity in the absence of ligand or coactivator 
recruitment [13]. These data demonstrate that the reported functions of PPARβ/δ 
upstream and downstream of PGC-1α thereby are dispensable for PGC-1α function 
in an overexpression context (Figure 5A). These observations are consistent with cell 
culture-based experiments showing that PGC-1α strongly increased oxidative 
metabolism in the absence of PPARβ/δ in skeletal muscle cells [20]. It appears hence 
that PGC-1α regulates skeletal muscle oxidative metabolism by increasing the 
transcriptional activity of alternative transcription factors, some of which might even 
compensate for the loss of PPARβ/δ. In fact, PPARα, ERRα and ERRγ were 
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significantly up-regulated in both mTg and mKO/mTg skeletal muscle, suggesting 
that these transcription factors might play a more relevant function in the regulation 
of skeletal muscle metabolism by PGC-1α.  
 
The contribution of PPARβ/δ to the regulation of skeletal muscle metabolism seems 
to be more relevant in the context of ligand-induced activation. Accordingly, 
PPARβ/δ activation with synthetic ligands have been shown to be an efficient 
treatment for metabolic disorders [13,16,17,21], though it remains unclear whether 
this effect is mediated by skeletal muscle PPARβ/δ. Conversely, overexpression of 
PGC-1α in skeletal muscle is insufficient to evoke similar therapeutic benefits in 
young mice and even accelerates the development of insulin resistance when such 
animals are fed a high-fat diet [22], unless the mice are concomitantly exercised [23]. 
In old animals however, overexpression of PGC-1α in muscle prevents age-induced 
insulin resistance [24]. These findings indicate that in some pathological settings, 
PPARβ/δ activation might be more relevant than PGC-1α, in particular in the 
absence of physical activity (Figure 5B). 
 
Surprisingly, in our study, mKO animals had a similar phenotype compared to CON 
mice, with minimal or no changes in body composition, blood parameters and gene 
expression. In contrast, Shuler et al. have reported higher body weight and fat, in 
addition to increased serum levels of glucose, insulin and TG in the same mouse 
model [11]. Intriguingly, similar discrepancies have been reported in global PPARβ/δ 
KO mouse models in regard to whole body metabolism assessed under basal 
conditions [17,25,26,27,28]. These differences in the phenotype of PPARβ/δ KO 
mouse models in chow fed sedentary condition might stem from different 
environmental factors (e.g. diet and temperature) that could lead to a partial 
PPARβ/δ activation in CON animals and thus lead to more pronounced phenotypic 
differences in metabolic parameters when compared to KO mice. 
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During exercise, skeletal muscle exerts a bigger impact on whole body metabolism 
compared to rest. Accordingly, mTg mice exhibit a higher VO2 and lower RER during 
treadmill running, reflecting an enhanced oxidative capacity and increased fatty acid 
oxidation [4]. Interestingly, while the PGC-1α-mediated improvement in VO2 during 
exercise is maintained in the absence of a functional PPARβ/δ gene, knockout of 
PPARβ/δ attenuated the decrease in the RER in mKO/mTg mice. In line with our 
observations, it has been shown that PPARβ/δ overexpression in skeletal muscle 
does not affect VO2 and RER during treadmill running [19]. Moreover, PPARβ/δ has 
been proposed to specifically regulate fatty acid metabolism and only to a smaller 
extent other oxidative metabolic genes in cultured muscle cells [20]. Together, these 
data suggest that the positive effects of skeletal muscle PGC-1α on VO2 are not 
dependent of PPARβ/δ, even though this nuclear receptor appears to be at least 
partially involved in the PGC-1α-mediated increase in fatty acid β-oxidation during 
exercise. In addition, by using these mouse models, our findings further support 
previous data suggesting that PGC-1α-controlled lactate metabolism is 
predominantly regulated by ERRα and not PPARβ/δ [18]. 
 
In summary, our results reveal important insights into the regulatory networks that 
control skeletal muscle plasticity. Here, we show that in normal/physiological 
conditions, PPARβ/δ is dispensable for the potent effect of PGC-1α on skeletal 
muscle remodeling. Importantly, the different therapeutic effects of PPARβ/δ and 
PGC-1α in the context of metabolic diseases during sedentary vs. exercise/aging 
state, strongly suggest that the relative importance of these molecules in controlling 
the metabolic phenotype of skeletal muscle varies significantly depending on the 
physiological and pathological context. Therefore, we hope that these findings will 
allow a more targeted dissection and modulation of skeletal muscle plasticity in 
health and disease in the future. 
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Materials and methods 
 
Animals 
Mice were housed in a conventional facility with a 12 h night and day cycle, with free 
access to food and water. All experiments were performed on adult male mice with 
approval of the Swiss authorities. PGC-1α muscle-specific transgenic (mTg) mice 
have been described previously [5]. PPARβ/δ muscle-specific knockout (mKO) mice 
were generated by crossing PPARβ/δloxP/loxP mice with HSA-Cre transgenic mice [11]. 
Finally, PGC-1α mTg and PPARβ/δloxP/loxP  mKO mice were crossed to generate 
mKO/mTg mice. PPARβ/δloxP/loxP animals without Cre and PGC-1α transgene 
expression were used as control (CON) mice. All mice had mixed sv129 and C57BL/6 
background. Genotypes were confirmed through standard PCR procedures (data not 
shown), in addition to qPCR analysis in kidney, gastrocnemius and tibialis anterior 
(Supplemental Figure 1, A and B). 
 
PPARβ/δ Agonist Administration 
CON and mKO mice were subjected to an intra-peritoneal injection of either 0.9% 
NaCl (control) or 1 mg/kg of body weight of the PPARβ/δ agonist GW0742 (Tocris 
#2229), as previously described [29]. Gastrocnemius and plantaris were collected 8 h 
following drug administration and immediately frozen in liquid nitrogen. 
 
Body Composition Analysis 
Lean and fat mass were measured via magnetic resonance (EchoMRITM). 
 
Blood and Plasma Analysis 
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Blood samples were collected from fed and overnight fasted (16 h) mice. Blood 
glucose and lactate were measured with a glucose (Roche) and lactate (Nova 
Biomedical) meter under basal condition, while blood lactate was also measured 
following maximal exercise (at exhaustion; see maximal exercise test). For plasma 
analysis, blood was collected in lithium/heparin coated tubes (Microvette®) and 
plasma concentration of different lipids was measured using a cobas c 111 
instrument (Roche). 
 
Glucose and Insulin Tolerance Test 
Intra-peritoneal glucose tolerance tests (GTT) were carried out by injecting 2 g/kg of 
body weight of glucose after 16 h of fasting (overnight). Insulin tolerance tests (ITT) 
were performed by injecting 0.8 U/kg of body weight of insulin (Novo Nordisk) after 
6 h of fasting. In both tests, blood samples were obtained from the tail vein before 
and 30, 60, 90 and 120 min after glucose or insulin injection. Blood glucose was 
measured as described above. 
 
Indirect Calorimetry 
Animals were individually housed in a Comprehensive Lab Animal Monitoring System 
(Columbus Instruments) during an acclimatization period of 48 h with free access to 
food and water. Subsequently, indirect calorimetry was performed during 48 h and 
data analyzed with the Oxymax software (Columbus Instruments). 
 
Maximal Exercise Test 
Animals were acclimatized to treadmill running for two days. On the first day, mice 
ran in a closed treadmill (Columbus Instruments) for 5 min at 8 m/min, followed by 5 
min at 10 m/min (5° slope was used during acclimatization and test). On the second 
day, animals ran for 5 min at 10 m/min, followed by 5 min at 12 m/min. To 
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determine maximal exercise performance, VO2peak and RER indirect calorimetry was 
performed during the test. Thus, two days after the acclimatization, mice were 
placed in a closed treadmill for 5 min at 0 m/min, the test subsequently started at 8 
m/min for 3 min and the speed increased 2 m/min every 3 min until exhaustion. 
 
Histology 
NADH staining was performed on 12 μm cross sections from plantaris by exposing 
them to 0.8 mg/mL NADH (Sigma #N8129) in the presence of 1 mg/mL nitro blue 
tetrazolium (Sigma #N5514). 
 
RNA Isolation and Quantitative PCR (qPCR) 
Total RNA was isolated by using lysing matrix tubes (MP Biomedicals) and TRI 
Reagent® (Sigma-Aldrich) according to the manufacturer’s instructions. RNA 
concentration was measured with a NanoDrop 1000 spectrophotometer (Thermo 
Scientific). One microgram of RNA was treated with DNase I (Invitrogen) and then 
reversed transcribed using hexanucleotide mix (Roche) and SuperScriptTM II reverse 
transcriptase (Invitrogen). Relative mRNA was quantified by qPCR on a StepOnePlus 
system (Applied Biosystems) using Power SYBR® Green PCR Master Mix (Applied 
Biosystems). The sequences of the qPCR primers are depicted in Supplemental Table 
1. Analysis was performed by the ΔΔCT method using TATA binding protein (TBP) as 
endogenous control. TBP transcript levels were not different between genotypes or 
different experimental conditions. 
 
Protein Isolation and Western Blot 
Samples were powdered on dry ice and homogenized in 300 μL of ice-cold sucrose 
lysis buffer (50 mM Tris-HCl pH 7.5, 250 mM Sucrose, 1 mM EDTA, 1 mM EGTA, 
0.25% Nonidet P 40 substitute, 50 mM NaF, 5 mM Na4P2O7, 0.1% DTT, fresh protease 
77 
CHAPTER 4: PGC-1α regulates skeletal muscle oxidative metabolism independently 
of PPARβ/δ 
and phosphatase inhibitor cocktail). Then, samples were shaken at 1300 rpm for 30 
min at 4°C. Samples were subsequently centrifuged at 13000 g for 10 min at 4°C and 
the protein concentration of the supernatant determined by the Bradford assay (Bio-
Rad). Equal aliquots of protein were boiled for 5 min in Laemmli sample buffer (250 
mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue and 5% β-
mercaptoetanol). 
Samples were separated on SDS-polyacrylamide gels and then transferred to 
nitrocellulose membranes for 1 h. Membranes were blocked for 1 h in 3% milk in 
Tris-buffered saline and 0.1% tween-20 (TBST) before overnight incubation at 4°C 
with appropriate primary antibody in TBST (1:1000 dilution). Proteins were detected 
with a primary antibody to Akt (Cell Signaling #9272), p-AktT308 (Cell Signaling #4056), 
AMPKα (Cell Signaling #2603), p-AMPKαT172 (Cell Signaling #2535) and total OXPHOS 
(Abcam #ab110413). As loading control, eEF2 (Cell Signaling: 2332) was used. 
Following incubation, membranes were washed 3 times with TBST before addition of 
an appropriate peroxidase-conjugated secondary antibody (Dako) in TBST (1:10000 
dilution). Antibody binding was detected using enhanced chemiluminescence HRP 
substrate detection kit (Pierce: 32106). 
 
Statistical Analysis  
Values are expressed as mean ± standard error of the mean (SEM). Statistical 
significance was determined with unpaired two-tailed t-tests or one-way ANOVA 
with Tukey’s post-hoc test. Significance was considered with a p < 0.05. 
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Figures 
 
Figure 1. PGC-1α and PPARβ/δ mouse models. (A and B) PGC-1α and PPARβ/δ 
mRNA levels in kidney, gastrocnemius (GAS) and tibialis anterior (TA) (n = 6 per 
group). (C and D) PPARβ/δ, UCP3 and ANGPTL4 mRNA levels in GAS and plantaris 
(PL) 8 h after the injection of 0.9% NaCl (as control) or 1 mg/kg of body weight of the 
PPARβ/δ agonist GW0742 (n = 6 per group). (E) mRNA level of different transcription 
factors and coregulators modulating energy metabolism in GAS (n = 6 per group). 
Values are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 2. Body composition, systemic parameters and glucose handling in PGC-1α 
and PPARβ/δ mouse models. (A) Assessment of body composition (n = 10-12 per 
group). (B and C) Plasma concentration of triacylglycerol (TAG), cholesterol (CHOL), 
low density lipoprotein (LDL) and high density lipoprotein (HDL) under fed and fasted 
conditions (n = 10-12 per group). (D and E) Measurement of oxygen consumption 
(VO2) (D) and respiratory exchange ratio (RER) (E) over a period of 48 h (n = 10-14 
per group). (F-H) Blood glucose levels during glucose (F) and insulin tolerance (G) 
tests. (H) Blood glucose levels in fed animals (n = 10-12 per group). (I) Gastrocnemius 
mRNA levels of genes involved in glucose metabolism (n = 6 per group). (J) Western 
blot assessment of Akt phosphorylation status in gastrocnemius (n = 6 per group). 
Values are mean ± SEM. *p < 0.05, **p < 0.01. In F §p < 0.05 mKO vs. mTg; ‡‡‡p < 
0.001 mKO vs. mKO/mTg. 
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Figure 3. Skeletal muscle PGC-1α modulates whole body metabolism during 
maximal exercise. (A and B) Maximal speed and time achieved during exercise tests 
to exhaustion (n = 10-12 per group). (C and D) Measurement of oxygen consumption 
(VO2) and respiratory exchange ratio (RER) during the maximal exercise test (n = 10-
12 per group). (E) Blood lactate levels before (PRE) and after (POST) maximal 
exercise (n = 10-12 per group). (F) mRNA levels of key genes of lactate metabolism in 
gastrocnemius (n = 6 per group). Values are mean ± SEM. *p < 0.05, **p < 0.01, ***p 
< 0.001. In C and D *p < 0.05, **p < 0.01, ***p < 0.001 CON vs. mTg; #p < 0.05, ##p < 
0.01 CON vs. mKO/mTg; §p < 0.05, §§§p < 0.001 mKO vs. mTg;  ‡‡p < 0.01 mKO vs. 
mKO/mTg. 
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Figure 4. Oxidative metabolism of gastrocnemius is enhanced by PGC-1α even in 
the absence of PPARβ/δ. (A and B) mRNA levels of genes regulating oxidative and 
fatty acid metabolism (n = 6 per group). (C) Western blot analysis of key proteins 
regulating the ETC (n = 6 per group). (D) Assessment of oxidative muscle fibers (dark 
blue) via NADH staining (n = 3 per group). (E) Western blot analysis of AMPK 
phosphorylation status (n = 6 per group). Values are mean ± SEM. *p < 0.05, **p < 
0.01, ***p < 0.001. 
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Figure 5. Regulation of the oxidative phenotype of skeletal muscle cells in health 
and disease. (A) In normal, physiological conditions, PPARβ/δ function is dispensable 
for PGC-1α-mediated remodeling of muscle metabolism. (B) In metabolic diseases, 
activation of PPARβ/δ with synthetic agonists relieves many disease symptoms 
whereas overexpression of muscle PGC-1α is insufficient to ameliorate insulin 
sensitivity in the absence of concomitant bona fide exercise. 
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Supplemental information 
 
Figure S1. Influence of the PGC-1α-PPARβ/δ axis on whole body metabolism. (A 
and B) Analysis of oxygen consumption (VO2) (A) and respiratory exchange ratio 
(RER) (B) over a period of 48 h (n = 10-14 per group). Values are mean ± SEM. 
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Table S1 qPCR Primer sequences 
Target gene Forward primer Reverse primer 
NDUFB5 TTTTCTCACGCGGAGCTTTC TGCCATGGTCCCCACTGT 
SDHa GCTGGTGTGGATGTCACTAAGG CCCACCCATGTTGTAATGCA 
CS CCCAGGATACGGTCATGCA GCAAACTCTCGCTGACAGGAA 
FH1 TGCTCTCAGTGCAAAATCCAA CGTGTGAGTTCGCCCAATT 
MCAD AACACTTACTATGCCTCGATTGCA CCATAGCCTCCGAAAATCTGAA 
HADHb TGCTGTCAGGCACTTCGTATAAA AAACCCGAAAGTGCAGCTCTAG 
PFK TGTGGTCCGAGTTGGTATCTT GCACTTCCAATCACTGTGCC 
HK2 CCCTGCCACCAGACGAAA GACTTGAACCCCTTAGTCCATGA 
LDHa CATTGTCAAGTACAGTCCACACT TTCCAATTACTCGGTTTTTGGGA 
LDHb CATTGCGTCCGTTGCAGATG GGAGGAACAAGCTCCCGTG 
CPT1b ATCATGTATCGCCGCAAACT CCATCTGGTAGGAGCACATGG 
ACC GGGCTCGGGCATGATTG CAGGTAAGCCCCGATTCCA 
MCD ACTCCATCAGCCTGACCCAG ACCCCTTGAGGCTCTCGTGA 
TBC1D1 CATAAAGAACACACTCCCCAACCT TGCTTGGCGATGTCCATCT 
TBC1D4 GTACCGACCGGATATGATGTCA CGGTGGTAGTCATGAAGGAGTCT 
GLUT4 CATGGCTGTCGCTGGTTTC AAACCCATGCCGACAATGA 
MCT1 GTGACCATTGTGGAATGCTG CTCCGCTTTCTGTTCTTTGG 
MCT4 TCACGGGTTTCTCCTACGC GCCAAAGCGGTTCACACAC 
PGC-1α AGCCGTGACCACTGACAACGAG GCTGCATGGTTCTGAGTGCTAAG 
PGC-1β CCATGCTGTTGATGTTCCAC GACGACTGACAGCACTTGGA 
PRC  CACCCTGCCGGAGTGAAAT CGCATTGACTGCTGCTTGTC 
ND1 TCTGCCAGCCTGACCCATA GGGCCCGGTTTGTTTCTG 
ATP6 ACTATGAGCTGGAGCCGTAATTACA TGGAAGGAAGTGGGCAAGTG 
CyC AAATCTCCACGGTCTGTTCG TATCCTCTCCCCAGGTGATG 
SDHb TGACGTCAGGAGCCAAAATGG CCTCGACAGGCCTGAAACTG 
PDK4 AAAATTTCCAGGCCAACCAA CGAAGAGCATGTGGTGAAGGT 
UCP3 TTTTGCGGACCTCCTCACTT TGGATCTGCAGACGGACCTT 
ANGPTL4 GCGTAAAAAGGGTATCTTCTGGAA GGTGGTAGCCTGCAGAGGATAG 
SLC25a20 CTGCGCCCATCATTGGA CAGACCAAACCCAAAGAAGCA 
FABPpm AGCGGCTGACCAAGGAGTT GACCCCTGCCACGGAGAT 
PPARβ/δ GCAGACCTCTCCCAGAATTCC ACACCCGACATTCCATGTTGA 
PPARα GCGTACGGCAATGGCTTTAT ACAGAACGGCTTCCTCAGGTT 
PPARγ CCCACCAACTTCGGAATCAG AATGCGAGTGGTCTTCCATCA 
ERRα CGGTGTGGCATCCTGTGA CTCCCCTGGATGGTCCTCTT 
ERRβ CCCTGACCACTCTCTGTGAATTG TGGCCCAGTTGATGAGGAA 
ERRγ GCCCAGCCACGAATGAAT GCAGGCCTGGCAGGATTT 
TFAM GGTCGCATCCCCTCGTCTA GGATAGCTACCCATGCTGGAAA 
TBP TGCTGTTGGTGATTGTTGGT CTGGCTTGTGTGGGAAAGAT 
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Discussion 
Skeletal muscle tissue can exhibit drastic changes in its phenotype and thus 
directly affect whole body homeostasis. The effect of skeletal muscle in the 
modulation of whole body homeostasis and health status has been well reported in 
trained subjects, which in contrast to sedentary subjects, show lower risk of 
metabolic diseases and premature death (Booth et al., 2011; Booth and Roberts, 
2008). Skeletal muscle remodelling mediated by physical activity and inactivity is 
determined by the expression and repression of a highly specific subset of genes. 
While a number of transcription factors have been implicated in the control of these 
gene expression signatures, transcriptional coactivators and corepressors have 
emerged as key players in skeletal muscle remodelling (Egan and Zierath, 2013; 
Gundersen, 2011). Coregulators are able to modulate the activity of a subset of 
transcription factors regulating common biological processes, with significant 
physiological relevance and potential as therapeutic targets for diseases related to 
transcriptional deregulation (Lonard and O'Malley, 2012). Different coregulators 
have been studied in skeletal muscle tissue, including SRC-1, TIF2 and RIP140 (Duteil 
et al., 2010; Seth et al., 2007), but the coactivator PGC-1α and the corepressor 
NCoR1 show a high potential as regulators of skeletal muscle remodelling 
(Handschin, 2010; Mottis et al., 2013). However, the mechanism by which these 
coregulators modulate skeletal muscle plasticity is not fully understood. 
Interestingly, several transcription factors targeted by NCoR1 and some 
components of this corepressor complex are well-known regulators of skeletal 
muscle function (Bailey et al., 1999; Busson et al., 2005; Ishizuka and Lazar, 2005; 
Kitamura et al., 2007; McKenna and O'Malley, 2010), strongly suggesting a role of 
NCoR1 in skeletal muscle remodelling. Accordingly, during the first study of this 
thesis we used NCoR1 skeletal muscle-specific knockout (mKO) mice to define the 
function of skeletal muscle NCoR1. During the course of this study, an article 
describing the phenotype of this mouse model under basal conditions and following 
high-fat diet feeding reported that genetic ablation of NCoR1 in skeletal muscle 
improves exercise performance, enhance oxidative capacity and lower respiratory 
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exchange ratio (RER), primarily under high-fat diet feeding  (Yamamoto et al., 2011). 
In line with these data, our study revealed new evidence supporting the metabolic 
function of NCoR1, including an enhanced VO2peak during treadmill running, higher ex 
vivo fatigue resistance and increased proportion of oxidative fibres. These data 
demonstrate that NCoR1 is a negative regulator of skeletal muscle oxidative 
metabolism. Importantly, the fact that whole body oxidative capacity and skeletal 
muscle function are altered in NCoR1 mKO mice strongly highlight the physiological 
relevance of this corepressor. Interestingly, the gene expression signature and 
functional adaptations induced by skeletal muscle NCoR1 ablation resemble some 
aspects of endurance training (Egan and Zierath, 2013; Holloszy and Coyle, 1984). 
Hence, NCoR1 emerges as a potential modulator of skeletal muscle plasticity in 
contexts like physical activity and inactivity in which this corepressor would exhibit 
decreased and increased activity, respectively. 
We further studied the possible mechanisms by which NCoR1 modulates 
skeletal muscle remodelling. The phenotype of NCoR1 mKO mice suggest that this 
corepressor exerts opposite effects than PGC-1α on oxidative metabolism and 
skeletal muscle function (Calvo et al., 2008; Lin et al., 2002; Summermatter et al., 
2012), which has led to the idea of a functional interplay between these coregulators 
(Yamamoto et al., 2011). This interaction between NCoR1 and PGC-1α has been 
previously proposed to control PPARγ activity in adipocytes (Guan et al., 2005). In 
this study, by using bioinformatics and cell culture approaches, we directly explored 
this hypothesis. Microarray studies showed that, as speculated, NCoR1 and PGC-1α 
target a common subset of genes related to skeletal muscle oxidative metabolism, 
while cell culture experiments confirmed their functional interplay. PPARβ/δ and 
ERRα have been previously proposed to be directly repressed by NCoR1 (Yamamoto 
et al., 2011), while PGC-1α is well-known to activate both of these nuclear receptors 
(Ehrenborg and Krook, 2009; Giguere, 2008; Handschin, 2010). Consistently, further 
analysis of our microarray data predicted ERRα and the PPARs heterodimer partners 
RXRs as common targets of NCoR1 and PGC-1α. Importantly, both of these 
transcription factors have been demonstrated to promote the expression of key 
genes regulating energy metabolism (Ehrenborg and Krook, 2009; Giguere, 2008). As 
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predicted, we demonstrated that both of these transcription factors are directly 
regulated by NCoR1 and PGC-1α. To our surprise however, we found that only ERRα 
was required for NCoR1 to regulate skeletal muscle oxidative metabolism. This study 
therefore has revealed the key role of NCoR1 in skeletal muscle remodelling and 
function, providing new insights in the molecular mechanism by which the interplay 
between NCoR1 and PGC-1α regulate gene transcription. These results also suggest 
NCoR1 as a therapeutic target for the treatment of metabolic diseases, where NCoR1 
target genes seems to be down-regulated. In fact, NCoR1 mKO animals appear to be 
slightly protected against high-fat diet induced insulin resistance and whole body 
metabolic deregulation (Yamamoto et al., 2011). Inhibition of NCoR1 via exercise or 
pharmacological compounds would be expected then to improve skeletal muscle 
metabolic fitness and thus prevent the development of metabolic diseases. 
However, future studies are required to determine the therapeutic potential of 
skeletal muscle NCoR1 in the context of metabolic diseases. 
The molecular mechanism by which the coactivator PGC-1α regulates 
skeletal muscle metabolism was further examined during the second study of this 
thesis, where the functional interaction between PGC-1α and PPARβ/δ was directly 
assessed in vivo. As mentioned above, the transcriptional activity of the nuclear 
receptor PPARβ/δ is directly enhanced by PGC-1α (Dressel et al., 2003; Narkar et al., 
2008; Perez-Schindler et al., 2012) and it has been proposed to play an important 
role in skeletal muscle plasticity (Ehrenborg and Krook, 2009). Actually, exercise has 
been shown to up-regulate PPARβ/δ levels in skeletal muscle (Ehrenborg and Krook, 
2009). Moreover, genetic activation of PPARβ/δ strongly increases skeletal muscle 
oxidative metabolism and exercise performance (Wang et al., 2004). However, the 
phenotype exhibited by the mouse model mentioned above seems to exert supra-
physiological effects, since pharmacological activation of PPARβ/δ or the 
overexpression of a normal non-hyperactive form this nuclear receptor result in 
milder effects on skeletal muscle and whole body metabolism (Gan et al., 2011; 
Luquet et al., 2003; Narkar et al., 2008). Our results validate the well-known effects 
of PGC-1α overexpression on skeletal muscle metabolism, whereas we surprisingly 
found that PPARβ/δ was dispensable for these effects. In fact, skeletal muscle PGC-
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1α overexpression enhanced both VO2peak and the proportion of oxidative fibres in 
the absence and presence of functional PPARβ/δ. However, we found that the higher 
fatty acid oxidation observed in PGC-1α mTg mice during exercise was attenuated by 
PPARβ/δ ablation, consistent with similar studies performed in cultured muscle cells 
(Kleiner et al., 2009). Unexpectedly, we also found that PPARβ/δ mKO mice showed 
a similar phenotype than wild type mice, contrasting previously published results 
using the same mouse model (Schuler et al., 2006). These results however, might be 
related to different environmental factors modulating PPARβ/δ activity, such as 
temperature, food and activity. In fact, similar discrepancies have been reported in 
PPARβ/δ global knockout mice (Akiyama et al., 2004; Feng et al., 2011; He et al., 
2010; Lee et al., 2006; Peters et al., 2000). Thus, studying the interplay between 
PGC-1α and PPARβ/δ in the context of ligand-mediated activation of this nuclear 
receptor might reveal some levels of interdependence. 
Interestingly, these results are in line with the data from the first study of this 
thesis. In fact, while PGC-1α was completely required for NCoR1 knockdown to up-
regulate metabolic-related genes in C2C12 cells, pharmacological inhibition of 
PPARβ/δ had no effect. Similarly, PPARβ/δ knockout did not impair the increase of 
mRNA and protein content of metabolic-related genes observed in skeletal muscle 
from PGC-1α mTg animals. Further supporting these results, it has been 
demonstrated that, irrespectively of PPARβ/δ expression levels, PGC-1α efficiently 
enhances oxidative metabolism in C2C12 muscle cells (Kleiner et al., 2009). 
Furthermore, our data show that the regulation of common target genes of NCoR1 
and PGC-1α is fully dependent of ERRα activation. Interestingly, we observed that 
PGC-1α overexpression significantly enhanced the expression levels of ERRα, ERRβ 
and PPARα in a PPARβ/δ independent manner. It therefore seems that similar to the 
cell culture experiments performed during the first study, the regulation of skeletal 
muscle oxidative metabolism in vivo might require the activation of ERRα or other of 
the up-regulated transcription factors. However, the fact that PPARβ/δ was found to 
be directly regulated by NCoR1 and PGC-1α implies that this nuclear receptor might 
play a relevant function in skeletal muscle plasticity in a context dependent manner. 
105  
CHAPTER 6: Discussion and outlook 
In fact, PPARβ/δ mKO animals have been reported to be more susceptible to the 
metabolic dysregulation associated with aging and high-fat diet feeding (Schuler et 
al., 2006). In addition, administration of PPARβ/δ specific agonists are highly efficient 
in preventing the pathological effects of obesity and type 2 diabetes (Lee et al., 
2006; Tanaka et al., 2003; Wang et al., 2004), while when combined with exercise 
training, it enhances skeletal muscle adaptations (Narkar et al., 2008). Impairments 
in skeletal muscle PGC-1α activity have been suggested to contribute to the 
development of metabolic diseases (Mootha et al., 2003; Patti et al., 2003), while 
our results suggest a possible pathogenic role of NCoR1. Therefore, regulation of 
PPARβ/δ by NCoR1 and PGC-1α might be relevant in conditions like metabolic 
diseases and exercise training. 
Finally, we investigated the potential function of PGC-1α in mechanical 
overload-induced skeletal muscle remodelling, which represents a context in which 
this coactivator has not been previously studied. PGC-1α and its transcript variant 
PGC-1α4 have been demonstrated to efficiently prevent skeletal muscle loss under 
catabolic contexts such as denervation (Brault et al., 2010; Ruas et al., 2012; Sandri 
et al., 2006). In addition, the key regulator of skeletal muscle protein synthesis 
mTORC1 has been shown to regulate skeletal muscle metabolism through the 
modulation of PGC-1α-YY1 complex (Blattler et al., 2012; Cunningham et al., 2007). 
Hence, the mTORC1-PGC-1α axis seems to be a potential mechanism by which 
resistance exercise mediates skeletal muscle remodelling. Interestingly, our data 
show that while chronic skeletal muscle overload via synergist ablation (SA) strongly 
activates mTORC1 and promotes skeletal muscle hypertrophy, it actually down-
regulates PGC-1α and PGC-1α4 levels. Consistently, PGC-1α and PGC-1α4 were 
found to be dispensable for SA-induced skeletal muscle hypertrophy. Actually, 
microarray data generated in the first study of this thesis revealed that PGC-1α 
overexpression in skeletal muscle down-regulates the expression of genes related to 
ribosomes and anabolic process. These data suggest that PGC-1α does not promote 
skeletal muscle growth, which is consistent with cell culture experiments showing no 
effects of PGC-1α overexpression on protein synthesis (Brault et al., 2010). 
Moreover, resistance exercise in humans seems to induce different results, with 
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some studies showing no effect and others showing increased levels of skeletal 
muscle PGC-1α following resistance exercise (Apro et al., 2013; Coffey et al., 2006; 
Donges et al., 2012; Item et al., 2013; Ruas et al., 2012). The mechanism regulating 
mechanical overload-induced skeletal muscle hypertrophy is not fully understood, 
but it seems that PI3K-insulin-like growth factor 1 (IGF-1) and myostatin pathways 
play a minor role (Philp et al., 2011). Therefore, it remains to be determined whether 
the mTORC1-PGC-1α axis might play a role in mediating skeletal muscle remodelling 
in a context in which skeletal muscle hypertrophy is induced by growth factors. 
An important aim of this study was to investigate metabolic and functional 
adaptations induced by mechanical overload of skeletal muscle. Interestingly, we 
observed that the experimental model of SA does not fully resemble the effects 
induced by resistance exercise. While resistance exercise exerts mild or no effects on 
energy metabolism (Egan and Zierath, 2013), we found that SA induced a global 
repression of both glycolytic and oxidative metabolism in skeletal muscle, consistent 
thus with the negative effects of SA on PGC-1α levels. Actually, PGC-1α 
overexpression attenuated this metabolic repression. Further supporting these 
results, microarray studies have recently revealed that SA indeed represses a subset 
of genes related with mitochondrial function and oxidative metabolism (Chaillou et 
al., 2013). At the functional level, the results were also discordant, since resistance 
exercise increases maximal force (Egan and Zierath, 2013), whereas SA was found to 
decrease peak force and increase fatigue resistance. In fact, further analysis of genes 
regulating excitation contraction coupling revealed an increased expression of genes 
characteristic of slow-twitch muscle, while the respective fast isoforms of these 
genes were down-regulated. Interestingly however, while this fibre type switch 
toward a slow-contractile phenotype was not affected by PGC-1α overexpression, 
genetic ablation of this coactivator preserved muscle contractility after SA. These 
functional results are strongly supported by data demonstrating that expression of 
the fast-twitch related proteins MyHC-2B and myosin regulatory light chain (MLC) 
kinase 2 (MLCK2) was higher in skeletal muscle from PGC-1α mKO mice following SA, 
while MLC2 phosphorylation levels were also enhanced. Importantly, these data 
revealed a novel mechanism by which PGC-1α modulates skeletal muscle 
107  
CHAPTER 6: Discussion and outlook 
contractility, which significantly complements the mechanisms previously reported 
(Lin et al., 2002; Summermatter et al., 2012). Although SA did not fully resemble 
skeletal muscle remodelling induced by resistance exercise, the data obtained in this 
study strongly demonstrate that PGC-1α and PGC-1α4 do not regulate skeletal 
muscle hypertrophy and the metabolic remodelling induced by chronic overload of 
skeletal muscle. The relevance of these coactivators in different mouse models of 
resistance exercise remains to be elucidated. It is possible that different stimulation 
patterns (e.g. chronic vs. intermittent) better resembling resistance exercise would 
differentially regulate PGC-1α and PGC-1α4 expression, exerting then different 
effects on their target genes and thus skeletal muscle phenotype. However, there 
are clear limitations in terms of experimental models to achieve these aims, though 
chronic high frequency electrical stimulation of the sciatic nerve might represent a 
suitable approach. 
Collectively, these data demonstrate that the coregulators NCoR1 and PGC-
1α compete for the regulation of common transcription factors and target genes. 
Here, we have demonstrated that among these transcription factors, ERRα plays a 
major function in the control of skeletal muscle oxidative metabolism under basal 
conditions. Although we have demonstrated that these coregulators directly target 
PPARβ/δ, the relevance of this nuclear receptor remains to be studied under 
different contexts since it seems to be dispensable for the control of oxidative 
metabolism under basal conditions. Finally, we explored the potential role of the 
mTORC1-PGC-1α axis in skeletal muscle remodelling following mechanical overload. 
Our data strongly showed that neither PGC-1α nor PGC-1α4 is required for SA 
mediated hypertrophy, despite of strong mTORC1 activation. SA actually decreased 
PGC-1α and PGC-1α4 expression, repressing both glycolytic and oxidative 
metabolism. Importantly, this study revealed new PGC-1α targets involved in the 
regulation of skeletal muscle contractility under basal conditions and after SA. 
Overall, these results suggest that promoting NCoR1 exchange by PGC-1α at target 
genes represents a key step in the control of skeletal muscle remodelling, thus 
modulating this process represents an attractive strategy to improve skeletal muscle 
metabolic fitness and function.  
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Outlook 
The relevance of gene expression as a regulatory mechanism of skeletal 
muscle phenotype has been extensively reported under both physiological and 
pathological contexts. In the present study, we have identified novel mechanisms by 
which the interplay between coactivators and corepressors modulate skeletal 
muscle remodelling. The identification of NCoR1 as repressor of skeletal muscle 
metabolism through competition with PGC-1α opens new opportunities in the 
treatment of metabolic diseases. However, the physiological mechanism regulating 
NCoR1 and PGC-1α interaction needs to be determined. Considering the effects of 
endurance exercise on PGC-1α and skeletal muscle metabolism, it seems likely that 
NCoR1 might be inhibited by skeletal muscle contraction. This remains as an 
important open question, which might be addressed by assessing the effects of 
exercise on NCoR1 cellular localization, corepressor complex formation and 
promoter recruitment. Moreover, NCoR1 muscle-specific transgenic mice might be 
generated to directly determine the negative effects of NCoR1 on skeletal muscle 
remodelling following exercise training or pharmacological treatment of metabolic 
diseases. Moreover, assessing skeletal muscle NCoR1 activity in the context of 
metabolic diseases would reveal its potential pathogenic role and relevance as 
therapeutic target. 
Moreover, we have found that, under basal conditions, NCoR1 and PGC-1α 
regulate skeletal muscle remodelling in a PPARβ/δ independent manner. PPARβ/δ 
however has been demonstrated to be an efficient target for the treatment of 
metabolic diseases (Salvado et al., 2012). Hence, it is possible that these coregulators 
are required in the context of PPARβ/δ activation. It might be relevant thus to 
determine the functional interplay between NCoR1/PGC-1α and PPARβ/δ in either 
exercise training- or PPARβ/δ agonist-mediated skeletal muscle remodelling. In fact, 
it would be possible that under these contexts, PPARβ/δ activation by natural or 
pharmacological ligands might require the recruitment of PGC-1α to modulate 
biological functions different from those regulated by the PGC-1α-ERRα axis. 
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Finally, results from the last study indicate that PGC-1α does not mediate 
chronic overload-mediated skeletal muscle hypertrophy. However, the fact that this 
coactivator can inhibit protein degradation and prevent skeletal muscle atrophy 
strongly supports its therapeutic potential in the context of skeletal muscle wasting. 
Importantly, it remains to be determined if PGC-1α plays a regulatory role in an 
experimental model that better resembles the effects of resistance exercise in 
human skeletal muscle. Alternatively, PGC-1α might be more relevant in the context 
of skeletal muscle atrophy and re-growth following treatment with anabolic agents, 
such as IGF-1. The fact that PGC-1α4 was suggested to mediate skeletal muscle 
hypertrophy through IGF-1 and myostatin expression (Ruas et al., 2012) further 
support the idea that these coactivators might be relevant in the context of growth 
factor-induced hypertrophy. Therefore, even though these studies have revealed 
valuable information regarding coregulator-mediated skeletal muscle remodelling, 
future studies are required to fully determine the therapeutic potential of the new 
regulatory mechanisms that we have found. 
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